NASDAQ : SABS
SAB Biotherapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.35 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 304.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Details
| Name | SAB Biotherapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 86 |
| Founded | 2014 |
| Ceo | Samuel Reich |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US78397T2024 |
| Cusip | 78397T202 |
| Cik | 1833214 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Samuel J. Reich | Chief Executive Officer and Director |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President and Director |
| Lucy To | Executive Vice President and Chief Financial Officer |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive Vice President and Chief Medical Officer |
| Catherine DeRose | Vice President of Human Resources |
| Hua Wu Ph.D. | Senior Vice President of Product Development |
| Dr. Carlos N. Carillo M.Sc., Ph.D. | Senior Vice President of Regulatory Affairs |
| Angie Parizek | Senior Vice President of Clinical Operations |
Contact
| Address | 777 W 41st St., Miami Beach, Florida 33140, United States |
| Phone | 305 845 2813 |
| Website | https://www.sab.bio |